BRUKINSA as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.1
The efficacy and safety of BRUKINSA in the treatment of MZL were demonstrated in the MAGNOLIA study, a phase 2, open-label, multicentre, single-arm trial in patients with relapsed/refractory (R/R) MZL following at least one prior therapy including an anti-CD20-based therapy.2,3
In the MAGNOLIA trial, patients receiving BRUKINSA achieved an overall response rate (ORR) of 68%, with 26% of patients achieving a complete remission (CR). Responses were observed in all groups regardless of MZL subtype.3
BRUKINSA was generally well tolerated in the MAGNOLIA trial. Seven percent of patients discontinued due to adverse events (AEs) and there were no dose reductions due to AEs, demonstrating a favourable safety profile.3 The use of BRUKINSA for the treatment of adult patients with MZL who have received at least one prior anti-CD20-based therapy is supported by the National Institute of Health and Care Excellence (NICE).4